Is ERCC1 a reliable prognostic protein biomarker in non-small-cell lung cancer? | Thorax

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article Text

Miscellanea

Journal club

Is ERCC1 a reliable prognostic protein biomarker in non-small-cell lung cancer?

Free

Hannah J Durrington

Correspondence to Dr Hannah J Durrington, NIHR Clinical Lecturer in Respiratory Medicine, University of Manchester, AV Hill Building, Oxford Road, Manchester M13 9PT, UK; hannahd{at}doctors.org.uk

https://doi.org/10.1136/thoraxjnl-2013-204086

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Lung Cancer

After resection for non-small-cell lung cancer (NSCLC) cisplatin-based postoperative chemotherapy may be administered. How do we predict which patients will benefit from cisplatin chemotherapy?

This group previously published that the excision repair cross-complementation group 1 (ERCC1) protein acts as a prognostic biomarker, predicting the benefit of cisplatin-based chemotherapy after NSCLC resection. ERCC1 plays a crucial role in repairing DNA structures, damaged by cisplatin-based chemotherapy. Using immunohistochemical analysis, patients …